# NCT06770582 (NCT06770582)

> Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06770582
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Non-Muscle Invasive Bladder Urothelial Carcinoma; Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma; Stage I Bladder Cancer AJCC v8
- Interventions: Biospecimen Collection; Cisplatin; Computed Tomography; Fluorouracil; Gemcitabine; Magnetic Resonance Imaging; Mitomycin; Pembrolizumab; Questionnaire Administration; Radiation Therapy
- Enrollment: 160
- Primary outcome: Bladder intact event-free survival (BIEFS)
- Primary outcome: Global quality of life

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06770582